ReviewMedComm2026
Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular and membrane proteins serve important roles. They manage cellular communication, structure support, and immune defense. When they malfunction, it cause many diseases like cancer, neurodegeneration, and cardiovascular disorders. Targeted protein degradation (TPD) is a promising therapeutic strategy and aims to remove these faulty proteins. This approach goes beyond traditional drugs, which only block the active site of proteins. The aim of TPD is to entirely remove the targeted proteins in cells. This review began with explaining the structure and functions of extracellular and membrane proteins, highlighting their connection with disease. It then went on to discuss new strategies for their degradation. These emerging strategies include those that take advantage of cell-surface receptors to target lysosomes, intracellular lysosomal sorting tools, E3 ligases, and nanoparticle-based systems. A comparison of different TPD tools was also provided. Discussion compared strengths and weaknesses of approaches with small molecules, antibodies, nanobodies, and aptamers. Finally, the review outlined future directions for advanced TPD strategies. Next steps would be the combination of degraders with therapeutic antibodies. Another research interest is the utilization of tissue-specific receptors from genetic databases. Moreover, the application of TPD to immune and neurodegenerative diseases is also a critical goal for the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.